Series A Round

Field Medical, a San Diego-based company specializing in cardiac pulsed field ablation (PFA) technology, has successfully raised $40 million in a Series A funding round. The company is focused on developing next-generation pulsed field ablation tools to address unmet needs in arrhythmia care, particularly for conditions such as ventricular tachycardia (VT) and atrial fibrillation (AF). This funding will support the advancement of their innovative FieldForce Ablation system, which aims to redefine treatment protocols in cardiac care. The investment will also enable Field Medical to accelerate clinical trials and expand its research and development efforts. The company is poised to make significant strides in the cardiac care sector, leveraging this funding to enhance patient outcomes. The funding round was led by prominent investors in the medical technology space, reflecting strong confidence in Field Medical's vision and potential impact on cardiac treatment.